While the analysis of TCGA data indicated that the survival advantage associated with CD161 expression is consistent across a range of tumor types, we acknowledge the potential for inter-tumor heterogeneity to influence the immune microenvironment and the specific role of CD161. Here, KLRB1 is linked to neoplasm.